Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Hyatt Hotels Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Hyatt Hotels Corporation trades at $187.35 (market cap $18.19B). The key difference: Hyatt Hotels Corporation is far larger — about 4.1× ACADIA Pharmaceuticals Inc.'s market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | H | |
|---|---|---|
Market Cap | $4.49B | $18.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $202.09 |
52-Week Low | $20.06 | $135.01 |
Enterprise Value | $3.69B | $22.03B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Hyatt Hotels (H) trades at $193.16, up 0.98% with a neutral technical signal. The stock shows mixed fundamentals with negative net income margins (-0.48%) and ROE (-1.02%) despite revenue growth to $7.1B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, while analyst consensus targets $197.30. The company continues expansion with new hotel announcements and maintains strong institutional support.
Investment outlook is cautiously optimistic given analyst buy ratings (37.5%) and expansion initiatives, but risks include declining cash flow trends and elevated debt levels. The stock faces pressure from negative profitability metrics despite revenue stability, requiring careful monitoring of upcoming Q2 2026 earnings against the $0.89 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
